News and Announcements
Australian Patent Granted for Use of Midkine for Hair Growth
- Published January 13, 2015 1:49PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ASX; Published: Sydney, 12th January 2015
Cellmid Limited (ASX:CDY) has received official Notice of Acceptance from IP Australia for Cellmid’s patent application 2011220326.
This patent protects the use of midkine and the closely related protein pleiotrophin for use as a hair loss and/or hair growth treatments. The granted claims cover topical formulations of all kinds, including shampoos, conditioners,creams and lotions with protection until 2031.
This patent family adds to the already considerable intellectual property assets of Cellmid’s wholly owned anti-aging hair growth subsidiary, Advagen, which include patent protection and extensive know-how around its FGF5 inhabiting technologies, cell based assays, formulations and brands.
To read the full announcement please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
